Rapid, On-site HIV Testing: Increases Life Expectancy and Is Cost-effective
Providing rapid HIV testing in drug treatment programs is also a good investment of health care dollars. This study demonstrated that providing onsite rapid HIV testing was cost-effective using the Cost Effectiveness of Preventing AIDS Complications …
Read more on AIDS.gov blog (blog)

The Clash of the Six-Figure Drugs
“We are on par with” the cost of current treatment for the disorder, said Paula Soteropoulos, a Genzyme official. (That treatment, called apheresis, uses a machine to filter bad cholesterol out of the bloodstream.) Of course, doctors and patients will …
Read more on Wall Street Journal (blog)

European Officials Say Drug Makers Paid to Delay Generic Version
While the companies have said the payments were legitimate, the European Union's antitrust chief said Thursday that the money probably changed hands to keep lower-cost versions of a drug called fentanyl off the market in the Netherlands. European …
Read more on New York Times

Drug Makers See Profit Potential in Rare Diseases
… be priced lower than its rival Juxtapid. But Kynamro still will cost $ 176,000 a year, according to Sanofi's Genzyme unit, which developed the drug with Isis Pharmaceuticals Inc. A year's treatment of Juxtapid costs $ 235,000 to $ 295,000, depending …
Read more on Wall Street Journal